ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Pu...
September 11 2018 - 4:01PM
ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company
dedicated to changing lives through the creation of transformative
RNA medicines for the treatment of severe genetic rare diseases,
today announced the closing of its previously announced
underwritten public offering of 6,612,500 ordinary shares at a
price to the public of $15.75 per share. The
closing included the full exercise of the underwriters’ option to
purchase 862,500 additional ordinary shares at the public offering
price, less underwriting discounts and commissions. Gross
proceeds from the offering totaled approximately $104.1 million,
before deducting underwriting discounts and commissions and
offering expenses.
Citigroup, Evercore ISI and RBC Capital Markets
acted as joint bookrunners for the offering. H.C. Wainwright
& Co. and Chardan acted as co-managers for the offering.
Kempen & Co acted as the Company’s European financial advisor
in relation to this offering.
A shelf registration statement relating to the
offered ordinary shares was filed with the Securities and
Exchange Commission (SEC) on October 2, 2015, which was
declared effective on October 19, 2015. A prospectus
supplement and accompanying prospectus related to the offering have
been filed with the SEC and are available on the SEC's
website, located at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from Citigroup Global Markets
Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (800) 831-9146; Evercore
ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th
Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by
email at ecm.prospectus@evercore.com; or RBC Capital Markets,
LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New
York, NY 10281, or by telephone at (877) 822-4089, or by email at
equityprospectus@rbccm.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About ProQRProQR Therapeutics
is dedicated to changing lives through the creation of
transformative RNA medicines for the treatment of severe genetic
rare diseases such as Leber’s congenital amaurosis 10, dystrophic
epidermolysis bullosa and cystic fibrosis. Based on our unique
proprietary RNA repair platform technologies we are growing our
pipeline with patients and loved ones in mind.*Since 2012*
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to”, “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, statements about
ProQR’s business and efforts to develop RNA medicines. These
forward-looking statements involve risks and uncertainties, many of
which are beyond ProQR’s control. Applicable risks also include
those that are included in ProQR’s prospectus supplement and
accompanying prospectus filed with the SEC for the offering,
including the documents incorporated by reference therein, which
include ProQR’s Annual Report on Form 20-F for the year ended
December 31, 2017, and any subsequent SEC filings. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
ProQR Therapeutics N.V.:Smital ShahChief
Financial OfficerT: +1 415 231 6431ir@proqr.com
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Apr 2023 to Apr 2024